Pretreatment DST and hypothalamic-pituitary-adrenocortical function in depressed patients and comparison groups. A...

Area of Science:

• Neuroendocrinology
• Psychiatry
• Clinical Diagnostics

Background:

• The hypothalamic-pituitary-adrenocortical (HYPAC) axis is frequently dysregulated in mood disorders.
• The dexamethasone suppression test (DST) is a commonly used measure of HYPAC function.
• Previous studies suggested DST nonsuppression is a specific marker for depression.

Purpose of the Study:

• To re-evaluate the diagnostic utility of DST nonsuppression in major depressive disorder, mania, and healthy controls.
• To investigate the relationship between DST nonsuppression and specific depression subtypes.
• To explore alternative patterns of post-DST cortisol secretion and pre-treatment HYPAC measures.

Main Methods:

• Assessed pretreatment HYPAC function using plasma cortisol, urine free cortisol, and CSF cortisol levels.
• Administered the DST and measured plasma cortisol at multiple time points post-administration.
• Analyzed DST nonsuppression rates and cortisol levels across diagnostic groups (depressed, manic, healthy).

Main Results:

• DST nonsuppression was more frequent in depressed (35/111) and manic (8/16) patients than in healthy controls (8/77), but its predictive value for diagnostic category was lower than reported.
• Nonsuppression rates were similar in unipolar and bipolar depression and did not correlate with melancholic, endogenous, or psychotic subtypes.
• Pre-DST HYPAC measures were elevated in depressed patients compared to controls; age and body weight showed significant correlations with plasma cortisol levels.

Conclusions:

• DST nonsuppression has limited diagnostic specificity for major depressive disorder and mania.
• Pretreatment HYPAC function, indicated by elevated cortisol levels, is characteristic of depression.
• Further research is needed to understand the complex patterns of HYPAC regulation in mood disorders.